Profund Advisors LLC Purchases 3,316 Shares of Biogen Inc. $BIIB

Profund Advisors LLC grew its holdings in shares of Biogen Inc. (NASDAQ:BIIB) by 38.7% in the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 11,876 shares of the biotechnology company’s stock after acquiring an additional 3,316 shares during the period. Profund Advisors LLC’s holdings in Biogen were worth $2,683,000 as of its most recent SEC filing.

A number of other hedge funds have also bought and sold shares of BIIB. BlackRock Inc. acquired a new stake in shares of Biogen during the second quarter worth $3,453,878,000. Orbimed Advisors LLC bought a new position in Biogen in the 1st quarter worth approximately $11,293,000. Tidal Investments LLC raised its stake in Biogen by 9.0% during the 2nd quarter. Tidal Investments LLC now owns 63,842 shares of the biotechnology company’s stock valued at $13,794,000 after acquiring an additional 5,256 shares in the last quarter. Saudi Central Bank raised its stake in Biogen by 89.7% during the 2nd quarter. Saudi Central Bank now owns 10,273 shares of the biotechnology company’s stock valued at $2,220,000 after acquiring an additional 4,858 shares in the last quarter. Finally, Nippon Life Global Investors Americas Inc. acquired a new position in Biogen during the 2nd quarter worth $29,648,000. 87.93% of the stock is currently owned by institutional investors and hedge funds.

Biogen Price Performance

BIIB stock opened at $253.62 on Monday. Biogen Inc. has a twelve month low of $146.52 and a twelve month high of $258.78. The company has a market cap of $37.49 billion, a PE ratio of 108.38, a price-to-earnings-growth ratio of 2.88 and a beta of 0.10. The business’s 50-day simple moving average is $227.08 and its 200 day simple moving average is $201.04. The company has a quick ratio of 1.37, a current ratio of 1.95 and a debt-to-equity ratio of 0.39.

Biogen (NASDAQ:BIIB) last issued its earnings results on Wednesday, October 28th. The biotechnology company reported $2.62 earnings per share for the quarter, beating the consensus estimate of $1.99 by $0.63. The business had revenue of $2.80 billion for the quarter, compared to analyst estimates of $2.63 billion. Biogen had a net margin of 3.37% and a return on equity of 9.38%. The firm’s revenue was up 10.6% on a year-over-year basis. During the same period in the previous year, the business earned $4.81 EPS. On average, research analysts anticipate that Biogen Inc. will post 12.44 earnings per share for the current year.

Analyst Ratings Changes

A number of research firms have commented on BIIB. Piper Sandler restated an “overweight” rating and set a $245.00 price target (up from $225.00) on shares of Biogen in a research report on Thursday, September 3rd. Seaport Research Partners upgraded shares of Biogen to an “outperform” rating in a report on Monday, October 12th. Stifel Nicolaus set a $242.00 price objective on Biogen in a research report on Thursday, September 10th. HC Wainwright upped their price target on shares of Biogen from $237.00 to $251.00 and gave the stock a “buy” rating in a research note on Thursday, July 30th. Finally, Canaccord Genuity Group raised their price target on Biogen from $248.00 to $272.00 and gave the stock a “buy” rating in a research note on Thursday. One analyst has rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating, ten have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $251.00.

Biogen News Summary

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Better-than-expected Q3 results: Biogen reported adjusted earnings of $2.62 per share, above the $1.99 consensus estimate, while revenue reached $2.80 billion versus expectations of $2.63 billion. Revenue increased 10.6% year over year, supporting the view that the company is returning to growth. Biogen Reaches New 1-Year High on Better-Than-Expected Earnings
• Positive Sentiment: Analysts raised targets following the earnings beat: UBS lifted its target to $300, while Baird and Needham raised theirs to $290. Argus upgraded Biogen from “hold” to “buy” with a $280 target; RBC increased its target to $272 and retained an outperform rating. Canaccord Genuity also raised its target to $272 and assigned a buy rating. Analysts Increase Their Forecasts on Biogen After Upbeat Q3 Results
• Positive Sentiment: Growth narrative is improving: RBC analysts said Biogen’s quarterly performance suggests a growth-led comeback, potentially sustaining investor momentum after a period of declining results. Biogen Swings Back to Growth as Stock Momentum Could Continue
• Positive Sentiment: Alzheimer’s pipeline catalyst: Biogen plans to present long-term and real-world data at the November CTAD conference, including five-year Clarity AD extension data for lecanemab and additional Phase 2 CELIA data for diranersen. Positive results could strengthen confidence in the company’s Alzheimer’s portfolio and future growth prospects. Biogen to Present New Data Across Alzheimer’s Disease Portfolio at CTAD 2026
• Neutral Sentiment: Mixed analyst valuation signals: TD Cowen and Truist raised targets to $260, but those imply only modest upside from the current level. The concentration of target increases after earnings is supportive, although expectations are now higher.
• Negative Sentiment: Morgan Stanley remains cautious: The firm raised its target to $238 but kept an “equal weight” rating, indicating potential downside if Biogen’s growth recovery or pipeline data disappoints.

Biogen Company Profile

Biogen Inc is a biotechnology company that discovers, develops and commercializes therapies for neurological and neurodegenerative diseases. Its areas of focus include multiple sclerosis, Alzheimer’s disease, spinal muscular atrophy, amyotrophic lateral sclerosis and other serious medical conditions.

The company’s portfolio includes multiple sclerosis treatments such as Tecfidera, Vumerity, Tysabri, Plegridy and Avonex, as well as Spinraza for spinal muscular atrophy. Biogen also markets Leqembi, an Alzheimer’s disease treatment developed in collaboration with Eisai, and works with partners to advance additional therapies and biosimilars.

Biogen was founded in 1978 and is headquartered in Cambridge, Massachusetts.